Sagent Pharmaceuticals, Inc. Announces The Reintroduction Of Adenosine Injection, USP
4/21/2014 9:08:46 AM
SCHAUMBURG, Ill., April 21, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the reintroduction of Adenosine Injection, USP, an antiarrhythmic agent, now in improved prefilled plastic syringes. According to IMS, for the 12 months ending February 2014, the US market for Adenosine Injection, USP approximated $28 million. As with all products in Sagent's portfolio, Adenosine features Sagent's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.
Help employers find you! Check out all the jobs and post your resume.
comments powered by